Skip to main content
Figure 5 | Diabetology & Metabolic Syndrome

Figure 5

From: CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models

Figure 5

CNX-013-B2 ameliorates macro vesicular steatosis and increases liver glycogen. A- Liver weight in DIO and ob/ob mice, B- Liver TG in DIO and ob/ob mice, C-Liver cholesterol in DIO and ob/ob mice. D-Left panel-Hematoxylin-Eosin (H&E) stained sections of liver tissues from DIO mice at 100X magnification, D-Right panel-Hematoxylin-Eosin (H&E) stained sections of liver tissues from DIO mice at 100X magnification, periodic acid-Schiff (PAS) stain of liver sections of DIO mice at 100X magnification. Arrows showing glycogen deposits. All the values are expressed as Mean ± SEM; one way analysis of variance followed by Dunnett’s test for representing significance value of the treatment groups. P value significance was represented as (*) <0.05, (**) <0.01 and (***) <0.001 when compared with DIO control.

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us